Application of human serum albumin in the management of end-stage liver disease
10.3969/j.issn.1001-5256.2022.04.040
- VernacularTitle:人血白蛋白在终末期肝病中的应用
- Author:
Lu YANG
1
;
Ye XIONG
1
;
Jianrong HUANG
1
Author Information
1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, China
- Publication Type:Reviews
- Keywords:
Serum Albumin;
End Stage Liver Disease;
Therapeutics
- From:
Journal of Clinical Hepatology
2022;38(4):936-941
- CountryChina
- Language:Chinese
-
Abstract:
Albumin is the most abundant protein in human plasma, and its oncotic and non-oncotic functions can regulate various functions in human body. In patients with end-stage liver disease, the deterioration of disease conditions and related complications caused by the reduction, loss, and abnormal function of albumin can be alleviated or even improved to some extent after the treatment with human serum albumin. This article reviews recent clinical studies in China and foreign countries, discusses the application and clinical effect of human serum albumin in end-stage liver disease, and points out that effective monitoring of albumin content may become a new indicator for the prognosis and treatment of end-stage liver disease.
